bioAffinity Technologies Reports Q1 Loss, Short Cash Runway, and Going Concern Warning

summarizeSummary

bioAffinity Technologies reported a wider Q1 net loss and a critical cash runway extending only through June 2026, reinforcing its going concern warning and urgent need for financing.

check_boxKey Events

• Going Concern Warning & Short Cash Runway

  The company explicitly states substantial doubt about its ability to continue as a going concern, with cash and cash equivalents of $1.7 million as of May 4, 2026, expected to fund operations only through June 2026.

• Increased Net Loss & Cash Burn

  Net loss for Q1 2026 widened to $3.6 million from $2.7 million in Q1 2025. Net cash used in operating activities nearly doubled to $3.2 million in Q1 2026 from $1.6 million in Q1 2025.

• Overall Revenue Decline Despite Product Growth

  Total net revenue decreased by 36% to $1.4 million in Q1 2026 compared to $1.9 million in Q1 2025, primarily due to discontinuing unprofitable pathology services. However, CyPath® Lung diagnostic test revenue grew 114% year-over-year.

• Shareholder Approval for Increased Equity Incentive Plan Shares

  As a subsequent event on April 30, 2026, shareholders approved increasing the authorized shares for the 2024 Equity Incentive Compensation Plan from 66,666 to 1,000,000 shares, providing significant headroom for future equity compensation.

auto_awesomeAnalysis

bioAffinity Technologies has reported a significant increase in net loss and cash burn for Q1 2026, leading to a critical liquidity position. The company's cash and cash equivalents of $1.7 million as of May 4, 2026, are expected to fund operations only through June 2026. This short cash runway, coupled with an explicit going concern warning, highlights an urgent need for additional capital. While the CyPath® Lung diagnostic test showed strong revenue growth, overall revenue declined due to the discontinuation of other services, and operating expenses rose significantly. The company will need to secure substantial financing to continue operations, which could involve further dilutive equity or debt offerings.